Thus, in the current study, we aim to confirm the role of complement provoked NLRP3 activation in the occurrence and progression of PAH and evaluate the curative efficacy of the newly identified selective C3 inhibitor CP40-KK in the MCT-induced rat PAH model. Here, NLRP3 is linked to pulmonary arterial hypertension.